MedTrace Logo

Gene-by-Stress Interactions in Intervention Studies Significance

NCT03011645 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-02-17

No results posted yet for this study

Summary

The purpose of this study is to identify gene variants that increase risk of cardiovascular disease (CVD) and type 2 diabetes, particularly genes related to stress factors.

Conditions

Interventions

DRUG

Ziprasidone

Given by mouth, single dose of 60 mg.

DRUG

Lorcaserin

Given by mouth, single dose of 20 mg.

DRUG

Placebo Oral Tablet

Given by mouth, single dose.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • William E Kraus, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-24
Primary Completion
2020-01-28
Completion
2020-01-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03011645 on ClinicalTrials.gov